This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Deihimi S , Lev A , Slifker M , Shagisultanova E , Xu Q , Jung K , Vijayvergia N , Ross EA , Xiu J , Swensen J , Gatalica Z , Andrake M , Dunbrack RL , El-Deiry WS
BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations
Oncotarget. 2017 Jun 20;8(25) :39945-39962
PMID: 28591715 PMCID: PMC5522275 URL: https://www.ncbi.nlm.nih.gov/pubmed/28591715
AbstractDeficient mismatch repair (MMR) and microsatellite instability (MSI) contribute to ~15% of colorectal cancer (CRCs). We hypothesized MSI leads to mutations in DNA repair proteins including BRCA2 and cancer drivers including EGFR. We analyzed mutations among a discovery cohort of 26 MSI-High (MSI-H) and 558 non-MSI-H CRCs profiled at Caris Life Sciences. Caris-profiled MSI-H CRCs had high mutation rates (50% vs 14% in non-MSI-H, P < 0.0001) in BRCA2. Of 1104 profiled CRCs from a second cohort (COSMIC), MSH2/MLH1-mutant CRCs showed higher mutation rates in BRCA2 compared to non-MSH2/MLH1-mutant tumors (38% vs 6%, P < 0.0000001). BRCA2 mutations in MSH2/MLH1-mutant CRCs included 75 unique mutations not known to occur in breast or pancreatic cancer per COSMIC v73. Only 5 deleterious BRCA2 mutations in CRC were previously reported in the BIC database as germ-line mutations in breast cancer. Some BRCA2 mutations were predicted to disrupt interactions with partner proteins DSS1 and RAD51. Some CRCs harbored multiple BRCA2 mutations. EGFR was mutated in 45.5% of MSH2/MLH1-mutant and 6.5% of non-MSH2/MLH1-mutant tumors (P < 0.0000001). Approximately 15% of EGFR mutations found may be actionable through TKI therapy, including N700D, G719D, T725M, T790M, and E884K. NTRK gene mutations were identified in MSH2/MLH1-mutant CRC including NTRK1 I699V, NTRK2 P716S, and NTRK3 R745L. Our findings have clinical relevance regarding therapeutic targeting of BRCA2 vulnerabilities, EGFR mutations or other identified oncogenic drivers such as NTRK in MSH2/MLH1-mutant CRCs or other tumors with mismatch repair deficiency.
Notes1949-2553 Deihimi, Safoora Lev, Avital Slifker, Michael Shagisultanova, Elena Xu, Qifang Jung, Kyungsuk Vijayvergia, Namrata Ross, Eric A Xiu, Joanne Swensen, Jeffrey Gatalica, Zoran Andrake, Mark Dunbrack, Roland L El-Deiry, Wafik S Journal Article United States Oncotarget. 2017 Jun 20;8(25):39945-39962. doi: 10.18632/oncotarget.18098.